Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Otsuka HD: Sales of Healthcare Products Up to ¥676.7 Bil.
June 1, 2009
- GENERICS NEWS IN BRIEF
June 1, 2009
- Zeria: Mid-Term Sales Target Down to ¥73 Bil.
June 1, 2009
- Quintiles Named Most Favored CRO in 2 Independent Surveys
June 1, 2009
- ASKA: Profits Plummet with Flat Sales
June 1, 2009
- 60% of Patients Prefer In-House Prescriptions at Sanjou Hospital
June 1, 2009
- Seikagaku: Sales of Artz Up in Japan, China
June 1, 2009
- Cumulative Total of 787 Deaths Reported in Iressa-Treated Patients
June 1, 2009
- REGULATORY NEWS IN BRIEF
May 25, 2009
- BUSINESS NEWS IN BRIEF
May 25, 2009
- FDA Approves ACTOplus met XR: Takeda
May 25, 2009
- 31 Generics of Cravit from 23 Firms Included in NHI Price List
May 25, 2009
- First Generics Listed for 13 APIs
May 25, 2009
- Kyowa Kirin: Nesp Injection Plastic Syringe
May 25, 2009
- Mediceo Paltac to Invite 1,000 Employees to Early Retirement
May 25, 2009
- IMS Health Revises Its Forecast for Global Drug Sales Downward
May 25, 2009
- Kyowa Kirin Licenses Anti-LIGHT Antibody to sanofi-aventis
May 25, 2009
- JCR (Japan College of Rheumatology) 2009
May 25, 2009
- Shionogi to Acquire Pain-Focused US Company
May 25, 2009
- CS Yakuhin to Acquire Part of OTC Drugs Wholesale Business from Tomita Health Care
May 25, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…